Senvok Medical

Senvok Medical

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Senvok Medical is a commercial-stage medical device company focused on emergency response and wound management. It offers a direct-to-consumer and B2B product portfolio centered on anti-choking rescue devices, non-invasive wound closure systems, and ancillary wound care products. The company targets a diverse market, including schools, senior care facilities, hospitals, hospitality, and public service agencies, with ready-to-use solution packages. Its strategy leverages global manufacturing partnerships and an e-commerce platform to drive accessibility and adoption.

Emergency MedicineWound Care

Technology Platform

Portfolio of physical emergency & wound care devices (anti-choking suction, non-invasive wound closure straps, dressings) bundled with training/compliance solutions for specific market verticals.

Funding History

2
Total raised:$15M
Series A$12M
Seed$3M

Opportunities

Large and growing global market for emergency and wound care products, especially non-invasive, easy-to-use devices.
Increasing institutional demand for compliant, turnkey emergency preparedness kits in schools, senior care, and public venues.
Direct-to-consumer e-commerce channel allows for bypassing traditional medical distribution and reaching end-users directly.

Risk Factors

High regulatory and product liability exposure, particularly for life-saving devices.
Intense competition from large established medtech companies and low-cost manufacturers.
Growth dependent on successful penetration of long-cycle B2B institutional sales and potential reliance on third-party manufacturing partners.

Competitive Landscape

Senvok operates in the crowded emergency medical supplies and wound care market, competing against giants like 3M, J&J, and Medline, as well as numerous DTC brands. Its differentiation is based on product design for ease-of-use, bundling into vertical-specific solutions, and a direct sales model. It does not appear to have a clear, defensible technological moat.